Sherry B, Mosser A G, Colonno R J, Rueckert R R
J Virol. 1986 Jan;57(1):246-57. doi: 10.1128/JVI.57.1.246-257.1986.
A collection of 35 mouse monoclonal antibodies, raised against human rhinovirus 14 (HRV-14), was used to isolate 62 neutralization-resistant mutants. When cross-tested against the antibodies in a neutralization assay, the mutants fell into four antigenic groups, here called neutralization immunogens: NIm-IA, -IB, -II, and -III. Sequencing the mutant RNA in segments corresponding to serotype-variable regions revealed that the amino acid substitutions segregated into clusters, which correlated exactly with the immunogenic groups (NIm-IA mutants at VP1 amino acid residue 91 or 95; NIm-II mutants at VP2 residue 158, 159, 161, or 162; NIm-III mutants at VP3 residue 72, 75, or 78; and NIm-IB mutants at two sites, either VP1 residue 83 or 85, or residue 138 or 139). Examination of the three-dimensional structure of the virus (M. G. Rossmann, E. Arnold, J. W. Erickson, E. A. Frankenberger, J. P. Griffith, H.-J. Hecht, J. E. Johnson, G. Kamer, M. Luo, A. G. Mosser, R. R. Rueckert, B. Sherry, and G. Vriend, Nature [London], 317:145-153, 1985) revealed that each of the substitution clusters formed a protrusion from the virus surface, and the side chains of the substituted amino acids pointed outward. Moreover, four of the amino acid substitutions, which initially appeared to be anomalous because they were encoded well outside the cluster groups, could be traced to surface positions immediately adjacent to the appropriate viral protrusions. We conclude that three of the four antigens, NIm-IB, -II, and -III, are discontinuous. Thus, the amino acid substitutions in all 62 mutants fell within the proposed immunogenic sites; there was no evidence for alteration of any antigenic site by a distal mutation.
一组针对人鼻病毒14型(HRV - 14)产生的35种小鼠单克隆抗体被用于分离62个中和抗性突变体。当在中和试验中与这些抗体进行交叉检测时,这些突变体分为四个抗原组,这里称为中和免疫原:NIm - IA、- IB、- II和- III。对与血清型可变区相对应的片段中的突变RNA进行测序发现,氨基酸替换聚集成簇,这与免疫原性组完全相关(NIm - IA突变体在VP1氨基酸残基91或95处;NIm - II突变体在VP2残基158、159、161或162处;NIm - III突变体在VP3残基72、75或78处;NIm - IB突变体在两个位点,要么是VP1残基83或85,要么是残基138或139)。对病毒三维结构的研究(M. G. 罗斯曼、E. 阿诺德、J. W. 埃里克森、E. A. 弗兰肯伯格、J. P. 格里菲斯、H. - J. 赫希特、J. E. 约翰逊、G. 卡默、M. 罗、A. G. 莫瑟、R. R. 吕克特、B. 谢里和G. 弗里恩德,《自然》[伦敦],317:145 - 153,1985)表明,每个替换簇都形成了从病毒表面突出的结构,并且被替换氨基酸的侧链向外指向。此外,最初似乎异常的四个氨基酸替换,因为它们在簇组之外编码良好,可以追溯到紧邻适当病毒突出结构的表面位置。我们得出结论,四个抗原中的三个,NIm - IB、- II和- III,是不连续的。因此,所有62个突变体中的氨基酸替换都落在提议的免疫原性位点内;没有证据表明远端突变会改变任何抗原位点。